Publications by authors named "Alessandra M A Maciel"
Article Synopsis
- Chronic hepatitis C (CHC) is linked to liver damage due to the immune response to HCV antigens, with high levels of IL-1β, IL-6, and IL-17 found in patients.
- A notable increase in core-specific IL-6 and IL-17 T cells occurs in patients with more severe liver lesions, as shown by the Metavir scale.
- CHC patients have an elevated percentage of Treg cells, particularly those with advanced fibrosis, but a low proportion of CD39 Treg subsets, indicating an imbalance in T cell populations associated with liver fibrosis severity.
Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C.
Osong Public Health Res Perspect
April 2018
Objectives: To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV).
Methods: 4 questionnaires were used to evaluate PROs before, during and after treatment: Short Form-36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ) - hepatitis C virus (HCV), Work Productivity and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).
Results: Of the global sample of 55 patients included in this study; SOF + DCV ( = 10); SOF + DCV + RBV ( = 29); SOF + SMV ( = 16) all had a statistically significant improvement in SF-36, CLDQ and FACIT-F scores during and post-treatment.
Studies have suggested the pivotal role of T helper type 1 (Th1) -related cytokines on the outcome of hepatitis C virus (HCV) infection. Nevertheless, the role of different interleukin-17 (IL-17) -secreting T cells on chronic hepatitis C (CHC) is less clear. Here, the in vivo IL-1β, IL-6, and IL-17 levels were positively correlated with both alanine transaminase (ALT) levels and hepatic lesions.
View Article and Find Full Text PDF